 The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech stocks that hit 52-week highs on Dec. 12. Allergan plc NYSE: AGN Amgen, Inc. NASDAQ: AMGN received approval for its bone-building osteoporosis drug in the U.S. Aprea Therapeutics Inc NASDAQ: APRE Aptose Biosciences Inc NASDAQ: APTO Aurinia Pharmaceuticals Inc NASDAQ: AUPH Avenue Therapeutics Inc NASDAQ: ATXI submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting Bausch Health Companies Inc NYSE: BHC reacted to upgrade to Overweight rating by JPMorgan BioNTech SE ADR NASDAQ: BNTX Bio-Rad Laboratories, Inc. Class A NYSE: BIO Boston Scientific Corporation NYSE: BSX Bristol-Myers Squibb Co NYSE: BMY Deciphera Pharmaceuticals Inc NASDAQ: DCPH Eidos Therapeutics Inc NASDAQ: EIDX ESSA Pharma Inc NASDAQ: EPIX Flexion Therapeutics Inc NASDAQ: FLXN Forty Seven Inc NASDAQ: FTSV Globus Medical Inc NYSE: GMED reacted to upgrade to Overweight by Wells Fargo Securities Gossamer Bio Inc NASDAQ: GOSS Hologic, Inc. 